Article Versions Notes

Halatsch M-E, Dwucet A, Schmidt CJ, Mühlnickel J, Heiland T, Zeiler K, Siegelin MD, Kast RE, Karpel-Massler G. In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. Pharmaceuticals. 2021; 14(12):1241. https://doi.org/10.3390/ph14121241

Halatsch, Marc-Eric, Annika Dwucet, Carl Julius Schmidt, Julius Mühlnickel, Tim Heiland, Katharina Zeiler, Markus D. Siegelin, Richard Eric Kast, and Georg Karpel-Massler. 2021. "In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma" Pharmaceuticals 14, no. 12: 1241. https://doi.org/10.3390/ph14121241

Halatsch, M.-E., Dwucet, A., Schmidt, C. J., Mühlnickel, J., Heiland, T., Zeiler, K., Siegelin, M. D., Kast, R. E., & Karpel-Massler, G. (2021). In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. Pharmaceuticals, 14(12), 1241. https://doi.org/10.3390/ph14121241